Evolving Global Regulatory Frameworks for Drug Discovery and Development: Harmonization and Future Directions

INTRODUCTION: Global regulatory frameworks for drug discovery and development have gradually evolved from fragmented, region-specific approaches to increasingly harmo-nized systems designed to reduce complexity and accelerate quality access of medicines to patients. The recent reforms emphasize convergence through guidelines such as the ICH and the adoption of digital standards like CTD and eCTD, notwithstanding regional dissonance. Indeed, over 70 regulatory authorities have adopted ICH guidelines over the past 10 years, and over 90% of new drug applications in the major markets use CTD/eCTD formats, indicating a significant convergence. METHOD: A systematic literature review was conducted to examine changes in regulations, harmonization strategies undertaken by various regions worldwide, and lifecycle management strategies across regions. Emphasis was given to qualitative study and case study analysis to create awareness regarding various trends of accelerated review pathways. The analysis of comparative metrics regarding surveillance capacity was undertaken alongside an accelerated pathway. RESULTS: The study reported that global initiatives, i.e., ICH initiatives, as well as other regional harmonization initiatives like AMRH/ASEAN, resulted in a reduction of 25-40% of redundant conduct in clinical trials and a more effective use of resources. However, regions like Asia Pacific and China have seen a 20-30% reduction in approvals of oncology lifecycle models, as well as a 50-60% increase in approval of oncology trials, still lagging behindin filing, en-forcement, and technological adaptation. DISCUSSION: Harmonization limits data redundancy; however, regulatory divergence remains a challenge, especially in areas of post-market surveillance, AI/ML regulation, and frame-works on risk-benefit evaluation. Further, as reiterated, a more efficient drug development process is a by-product of harmonization efforts; however, as there is great variation in regu-latory philosophy, as illustrated through a comparative overview of FDA/GCC regulations, robust risk-based frameworks are pivotal. CONCLUSION: The future of global drug regulation lies in harmonizing innovative accelerated pathways with enhanced post-market surveillance. Policy reforms must continue to advance international convergence, addressing the unique challenges posed by local regulatory envi-ronments to support a more efficient and safe global drug development environment.